Apr 21, 2020
CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)
Feb 11, 2020
PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
Jan 30, 2020
Kedrion Biopharma Announces Completion of Enrollment for CARES10, a Phase 3, Multi-Center Study to Assess a 10 Percent Intravenous Immunoglobulin in Adults with Primary Immunodeficiency Disease
Jan 21, 2020
BioMatrix Specialty Pharmacy Selected As Authorized Provider Of Cutaquig
Dec 12, 2019
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
Dec 09, 2019
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sep 13, 2019
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
Jul 04, 2019
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
Jun 20, 2019
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
Apr 18, 2019
The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025
Apr 15, 2019
Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome
Mar 26, 2019
Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Jan 14, 2019
Intravenous Immunoglobulin (IVIG) Market to Reach $12.63 Bn, Globally, by 2022 at 7.1% CAGR, Says AMR
Nov 08, 2018
U.S. Intravenous Immunoglobulin (IVIG) Market Analysis & Outlook (2018-2025): Stringent Regulations Pertaining to Production & Approval is Hampering Growth
Oct 26, 2018
GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
Sep 12, 2018
Intravenous Immunoglobulin (IVIg) Treatment May Benefit Some Children with Autism Spectrum Disorder
Aug 02, 2018
A New Autoimmune Disease Is Found, Along with a Personalized Treatment for a Child's Rare Illness
Jul 20, 2018
CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
Jul 04, 2018
Intravenous Immunoglobulin (IVIg): World Strategic Business Outlook 2018-2024 - Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Jun 11, 2018
Global Immunoglobulin Products Market 2018-2024: Market to Grow with a CAGR of 8.5%